When Vas Narasimhan started as the new CEO of the Swiss drug giant Novartis, he began refocusing the company on a key business area: prescription medicines. Until recently, alongside top-selling ...

Novartis’ head of drug development Vas Narasimhan talks about the company’s stake in CAR-T immunotherapy. These cell therapies are set to transform treatment of blood cancers – but questions ...

Chief Executive Vas Narasimhan said in an interview with The Wall Street Journal. “The bar is very high, we need to find something that’s truly differentiated, that brings something new ...

At Novartis, CEO Vas Narasimhan’s overall 2024 pay increased by 6.9% at grant value, reaching 14.2 million Swiss francs ($15.7 million), according to the company’s annual report (PDF).

(Bloomberg) -- Moves by the incoming Trump Administration may be a boon to drugmakers, Novartis AG Chief Executive Officer Vas Narasimhan said, while concerns over vaccine policies and public ...

Vas Narasimhan, CEO of Swiss pharmaceutical company Novartis, struck a more cautious tone on the outlook for such miracle drug groups. Referring specifically to the obesity drug group, Narasimhan ...

Novartis Chief Executive Vas Narasimhan said in a call with reporters. Specifically, Narasimhan expects to get approval for a label expansion of the company’s prostate-cancer drug Pluvicto in ...

Positioning itself as a pure-play innovative medicines company, Novartis is bullish about the growth towards 2030 by placing an emphasis on a streamlined portfolio to drive sales, says CEO Vas ...